Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting

Todd M. Corneillie, Paul A. Whetstone, Claude F. Meares

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Antibodies against metal chelates may potentially be used in biomedical applications such as targeted imaging and therapy of cancer. Highly specific monoclonal antibodies can be developed, but their binding strength needs to be maximized for them to be of practical use. In general, the half-life for dissociation of an antibody-ligand complex is more than an order of magnitude lower than the half-lifetimes for decay of medically useful radiometal ions. Practically speaking, the metal chelate-based ligand will not be bound to its receptor long enough for all of the bound radiometal to decay. A novel approach to this problem is a combination of synthetic chemistry and site-directed mutagenesis, to position a mildly reactive group on the metal chelate adjacent to a complementary reactive group on the antibody when the complex is formed. The partners are chosen to be sufficiently unreactive so that they coexist with other molecules in living systems without undergoing reaction. When the antibody-chelate complex is formed the effective local concentrations of the two groups can be non-physically large, so that a permanent link is formed in the complex even though no reaction occurs when the partners are free in solution.

Original languageEnglish (US)
Pages (from-to)882-890
Number of pages9
JournalJournal of Inorganic Biochemistry
Volume100
Issue number5-6
DOIs
StatePublished - May 2006

Fingerprint

Artificial Receptors
Metals
Antibodies
Immunologic Techniques
Ligands
Site-Directed Mutagenesis
Mutagenesis
Half-Life
Monoclonal Antibodies
Ions
Imaging techniques
Molecules
Neoplasms
Therapeutics

Keywords

  • DOTA
  • Imaging
  • Indium
  • Therapy
  • Yttrium

ASJC Scopus subject areas

  • Biochemistry
  • Inorganic Chemistry

Cite this

Irreversibly binding anti-metal chelate antibodies : Artificial receptors for pretargeting. / Corneillie, Todd M.; Whetstone, Paul A.; Meares, Claude F.

In: Journal of Inorganic Biochemistry, Vol. 100, No. 5-6, 05.2006, p. 882-890.

Research output: Contribution to journalArticle

Corneillie, Todd M. ; Whetstone, Paul A. ; Meares, Claude F. / Irreversibly binding anti-metal chelate antibodies : Artificial receptors for pretargeting. In: Journal of Inorganic Biochemistry. 2006 ; Vol. 100, No. 5-6. pp. 882-890.
@article{10e996dae4b74b62bfa4ca35e88aae2c,
title = "Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting",
abstract = "Antibodies against metal chelates may potentially be used in biomedical applications such as targeted imaging and therapy of cancer. Highly specific monoclonal antibodies can be developed, but their binding strength needs to be maximized for them to be of practical use. In general, the half-life for dissociation of an antibody-ligand complex is more than an order of magnitude lower than the half-lifetimes for decay of medically useful radiometal ions. Practically speaking, the metal chelate-based ligand will not be bound to its receptor long enough for all of the bound radiometal to decay. A novel approach to this problem is a combination of synthetic chemistry and site-directed mutagenesis, to position a mildly reactive group on the metal chelate adjacent to a complementary reactive group on the antibody when the complex is formed. The partners are chosen to be sufficiently unreactive so that they coexist with other molecules in living systems without undergoing reaction. When the antibody-chelate complex is formed the effective local concentrations of the two groups can be non-physically large, so that a permanent link is formed in the complex even though no reaction occurs when the partners are free in solution.",
keywords = "DOTA, Imaging, Indium, Therapy, Yttrium",
author = "Corneillie, {Todd M.} and Whetstone, {Paul A.} and Meares, {Claude F.}",
year = "2006",
month = "5",
doi = "10.1016/j.jinorgbio.2006.01.004",
language = "English (US)",
volume = "100",
pages = "882--890",
journal = "Journal of Inorganic Biochemistry",
issn = "0162-0134",
publisher = "Elsevier Inc.",
number = "5-6",

}

TY - JOUR

T1 - Irreversibly binding anti-metal chelate antibodies

T2 - Artificial receptors for pretargeting

AU - Corneillie, Todd M.

AU - Whetstone, Paul A.

AU - Meares, Claude F.

PY - 2006/5

Y1 - 2006/5

N2 - Antibodies against metal chelates may potentially be used in biomedical applications such as targeted imaging and therapy of cancer. Highly specific monoclonal antibodies can be developed, but their binding strength needs to be maximized for them to be of practical use. In general, the half-life for dissociation of an antibody-ligand complex is more than an order of magnitude lower than the half-lifetimes for decay of medically useful radiometal ions. Practically speaking, the metal chelate-based ligand will not be bound to its receptor long enough for all of the bound radiometal to decay. A novel approach to this problem is a combination of synthetic chemistry and site-directed mutagenesis, to position a mildly reactive group on the metal chelate adjacent to a complementary reactive group on the antibody when the complex is formed. The partners are chosen to be sufficiently unreactive so that they coexist with other molecules in living systems without undergoing reaction. When the antibody-chelate complex is formed the effective local concentrations of the two groups can be non-physically large, so that a permanent link is formed in the complex even though no reaction occurs when the partners are free in solution.

AB - Antibodies against metal chelates may potentially be used in biomedical applications such as targeted imaging and therapy of cancer. Highly specific monoclonal antibodies can be developed, but their binding strength needs to be maximized for them to be of practical use. In general, the half-life for dissociation of an antibody-ligand complex is more than an order of magnitude lower than the half-lifetimes for decay of medically useful radiometal ions. Practically speaking, the metal chelate-based ligand will not be bound to its receptor long enough for all of the bound radiometal to decay. A novel approach to this problem is a combination of synthetic chemistry and site-directed mutagenesis, to position a mildly reactive group on the metal chelate adjacent to a complementary reactive group on the antibody when the complex is formed. The partners are chosen to be sufficiently unreactive so that they coexist with other molecules in living systems without undergoing reaction. When the antibody-chelate complex is formed the effective local concentrations of the two groups can be non-physically large, so that a permanent link is formed in the complex even though no reaction occurs when the partners are free in solution.

KW - DOTA

KW - Imaging

KW - Indium

KW - Therapy

KW - Yttrium

UR - http://www.scopus.com/inward/record.url?scp=33646126500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646126500&partnerID=8YFLogxK

U2 - 10.1016/j.jinorgbio.2006.01.004

DO - 10.1016/j.jinorgbio.2006.01.004

M3 - Article

C2 - 16487590

AN - SCOPUS:33646126500

VL - 100

SP - 882

EP - 890

JO - Journal of Inorganic Biochemistry

JF - Journal of Inorganic Biochemistry

SN - 0162-0134

IS - 5-6

ER -